Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide

SIMPLE SUMMARY: Previous studies have reported an association between the ratio of neutrophils to lymphocytes circulating in blood and outcomes in patients with cancer. This study examined the association between lymphocyte and neutrophil counts and survival in a prospective trial of preoperative ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Skubitz, Keith M., Domingo-Musibay, Evidio, Lindgren, Bruce R., Cheng, Edward Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316699/
https://www.ncbi.nlm.nih.gov/pubmed/35884480
http://dx.doi.org/10.3390/cancers14143419
_version_ 1784754879515852800
author Skubitz, Keith M.
Domingo-Musibay, Evidio
Lindgren, Bruce R.
Cheng, Edward Y.
author_facet Skubitz, Keith M.
Domingo-Musibay, Evidio
Lindgren, Bruce R.
Cheng, Edward Y.
author_sort Skubitz, Keith M.
collection PubMed
description SIMPLE SUMMARY: Previous studies have reported an association between the ratio of neutrophils to lymphocytes circulating in blood and outcomes in patients with cancer. This study examined the association between lymphocyte and neutrophil counts and survival in a prospective trial of preoperative chemotherapy for high-grade soft-tissue sarcomas. A statistically significant association between overall survival was observed with the neutrophil/lymphocyte ratio. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that might suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should examine the role of lymphocyte-myeloid cell balance in sarcoma biology. ABSTRACT: Several studies have reported an association between levels of circulating blood cells, in particular the neutrophil to lymphocyte ratio (absolute neutrophil count (ANC)/absolute lymphocyte count (ALC)) and outcomes in patients with cancer. In the current study, the association between lymphocyte, neutrophil, monocyte, and platelet counts and survival was examined in a prospective trial of preoperative pegylated-liposomal doxorubicin and ifosfamide for high-grade soft-tissue sarcomas. A statistically significant association between overall survival, but not progression free-survival, was observed with the ANC/ALC ratio at a cutoff value of ≥2 and a statistically significant trend using a cutoff of ≥5. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that can suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should therefore examine the role of lymphocyte-myeloid cell balance in sarcoma biology.
format Online
Article
Text
id pubmed-9316699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93166992022-07-27 Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide Skubitz, Keith M. Domingo-Musibay, Evidio Lindgren, Bruce R. Cheng, Edward Y. Cancers (Basel) Article SIMPLE SUMMARY: Previous studies have reported an association between the ratio of neutrophils to lymphocytes circulating in blood and outcomes in patients with cancer. This study examined the association between lymphocyte and neutrophil counts and survival in a prospective trial of preoperative chemotherapy for high-grade soft-tissue sarcomas. A statistically significant association between overall survival was observed with the neutrophil/lymphocyte ratio. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that might suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should examine the role of lymphocyte-myeloid cell balance in sarcoma biology. ABSTRACT: Several studies have reported an association between levels of circulating blood cells, in particular the neutrophil to lymphocyte ratio (absolute neutrophil count (ANC)/absolute lymphocyte count (ALC)) and outcomes in patients with cancer. In the current study, the association between lymphocyte, neutrophil, monocyte, and platelet counts and survival was examined in a prospective trial of preoperative pegylated-liposomal doxorubicin and ifosfamide for high-grade soft-tissue sarcomas. A statistically significant association between overall survival, but not progression free-survival, was observed with the ANC/ALC ratio at a cutoff value of ≥2 and a statistically significant trend using a cutoff of ≥5. Our results suggest that a balance between the lymphocyte count and the number of circulating myeloid cells that can suppress lymphocyte function may be predictive of survival in patients with soft-tissue sarcomas. Future research should therefore examine the role of lymphocyte-myeloid cell balance in sarcoma biology. MDPI 2022-07-14 /pmc/articles/PMC9316699/ /pubmed/35884480 http://dx.doi.org/10.3390/cancers14143419 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skubitz, Keith M.
Domingo-Musibay, Evidio
Lindgren, Bruce R.
Cheng, Edward Y.
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title_full Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title_fullStr Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title_full_unstemmed Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title_short Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
title_sort prospective trial of neutrophil/lymphocyte ratio and other blood counts as biomarkers of survival among patients with high-grade soft tissue sarcomas treated with pegylated liposomal doxorubicin and ifosfamide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316699/
https://www.ncbi.nlm.nih.gov/pubmed/35884480
http://dx.doi.org/10.3390/cancers14143419
work_keys_str_mv AT skubitzkeithm prospectivetrialofneutrophillymphocyteratioandotherbloodcountsasbiomarkersofsurvivalamongpatientswithhighgradesofttissuesarcomastreatedwithpegylatedliposomaldoxorubicinandifosfamide
AT domingomusibayevidio prospectivetrialofneutrophillymphocyteratioandotherbloodcountsasbiomarkersofsurvivalamongpatientswithhighgradesofttissuesarcomastreatedwithpegylatedliposomaldoxorubicinandifosfamide
AT lindgrenbrucer prospectivetrialofneutrophillymphocyteratioandotherbloodcountsasbiomarkersofsurvivalamongpatientswithhighgradesofttissuesarcomastreatedwithpegylatedliposomaldoxorubicinandifosfamide
AT chengedwardy prospectivetrialofneutrophillymphocyteratioandotherbloodcountsasbiomarkersofsurvivalamongpatientswithhighgradesofttissuesarcomastreatedwithpegylatedliposomaldoxorubicinandifosfamide